Skip to content

BioNTech

US · BNTX #801 by market cap Listed 2019
80.96 -0.42 -0.52%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    A Quick Look at Today's Ratings for BioNTech(BNTX.US), With a Forecast Between $125 to $132
    Market Newswire · 2026/11/5
  • Rating change
    H.C. Wainwright Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $110
    Market Newswire · 2026/11/10
  • Rating change
    H.C. Wainwright Maintains BioNTech(BNTX.US) With Buy Rating, Cuts Target Price to $110
    Market Newswire · 2026/11/9
  • Rating change
    BioNTech Price Target Cut to $106.00/Share From $114.00 by Morgan Stanley
    Dow Jones · 2026/11/5
  • Rating change
    Goldman Sachs Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $127
    Market Newswire · 2026/11/6
  • Rating change
    BioNTech Is Maintained at Overweight by Morgan Stanley
    Dow Jones · 2026/11/5
  • Rating change
    Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $106
    Market Newswire · 2026/11/9
  • Rating change
    BioNTech Is Maintained at Buy by UBS
    Dow Jones · 2026/11/5
  • Rating change
    HC Wainwright & Co. Maintains Buy on BioNTech, Lowers Price Target to $110
    Benzinga · 2026/11/9
  • Citi Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $125
    Market Newswire · 2026/11/11
  • J.P. Morgan Maintains BioNTech(BNTX.US) With Hold Rating, Announces Target Price $93
    Market Newswire · 2026/11/19
  • Company notice
    BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)
    SEC · 2026/10/26
  • Company notice
    BioNTech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
    SEC · 2026/11/10
  • BioNTech May Be the Next Moderna. Even If It Isn't, the Stock Is a Buy. -- Barrons.com
    Barron's · 2026/11/12
  • BofA Securities Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $108
    Market Newswire · 2026/11/17
  • Company notice
    BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)
    SEC · 2026/11/3
  • Rating change
    BioNTech Price Target Raised to $93.00/Share From $92.00 by JP Morgan
    Dow Jones · 2026/11/20
  • Company notice
    BioNTech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
    SEC · 2026/10/26
  • Company notice
    BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)
    SEC · 2026/11/3
  • BioNTech Is Maintained at Neutral by JP Morgan
    Dow Jones · 2026/11/20
  • Rating change
    BioNTech Price Target Cut to $125.00/Share From $140.00 by Wells Fargo
    Dow Jones · 2026/11/4
  • Rating change
    Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $106
    Benzinga · 2026/11/5
  • Revenue Beat: BioNTech SE Exceeded Revenue Forecasts By 24% And Analysts Are Updating Their Estimates
    Simply Wall St · 2026/11/5
  • Wells Fargo Maintains Overweight on BioNTech, Lowers Price Target to $125
    Benzinga · 2026/11/4
  • Rating change
    Evercore ISI Group Maintains Outperform on BioNTech, Lowers Price Target to $110
    Benzinga · 2026/11/4

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

BioNTech discussion 0 comments

Add a comment